&lt;p&gt;Clinical Value of SARS-CoV2 IgM and IgG Antibodies in Diagnosis of COVID-19 in Suspected Cases&lt;/p&gt;

Feng, Yilong

doi:10.2147/jir.s287733

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Several studies also observed IgG and IgM levels in patients with COVID-19. [27][28][29][30][31] A report by Li et al 24 showed increased IgG and IgM levels in 20 patients with confirmed COVID-19 at a relatively early stage of infection. Our results also reported that the production of IgG and IgM is dependent upon the severity of cases; in critical cases, the production of IgG and IgM was detectable as early as 5 days post symptom onset, similar to the observations of Park et al 32 Although the serological process for COVID-19 diagnosis supports other standard techniques, it has several limitations.…”

Section: Discussionmentioning

confidence: 98%

Detection of IgG and IgM Levels in Patients with COVID-19 in Mosul Province, Iraq

Kahya¹,

Mahmood²

2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has become the most dangerous viral infection worldwide. Since its identification in late 2019, the number of medical trials to combat the infection has sharply increased. Here, we investigated the profiles of IgG and IgM in 85 patients with confirmed SARS-CoV-2 infection from day 1 after symptom onset until day 35 with 5-day intervals. Serum samples were collected and stored until use. We observed that IgM levels were detectable on day 5 post symptom onset and increased sharply, with the highest rate detected in moderate cases (32.332 ± 4.32, n=10). Subsequently, a significant reduction in IgM was observed until it was undetectable on day 35 after symptom onset. Meanwhile, IgG levels were detected on day 10 post symptom onset, and the highest rate was observed in moderate cases (8.232 ± 2.3, n=10). A significant increase in IgG rate was observed in all patients, with the highest rate in moderate cases (42.432 ± 4.34, n=67) on day 35 post symptom onset. The statistical difference between the case and control groups was significant (p≤0.001). Two out of 85 patients died during the study.

show abstract

Section: Discussionmentioning

confidence: 98%

Detection of IgG and IgM Levels in Patients with COVID-19 in Mosul Province, Iraq

Kahya¹,

Mahmood²

2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

show abstract

“…If all antibody tests are positive, COVID-19 pneumonia could be confirmed. If not, nucleic acid detection (once or more) should be carried out, and in extreme cases, high-throughput viral genome sequencing is required [75].…”

Section: Antibody Testsmentioning

confidence: 99%

Development and Efficacy of Lateral Flow Point-of-Care Testing Devices for Rapid and Mass COVID-19 Diagnosis by the Detections of SARS-CoV-2 Antigen and Anti-SARS-CoV-2 Antibodies

Hsieh

Lin

et al. 2021

Diagnostics

View full text Add to dashboard Cite

The COVID-19 pandemic is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2020–2021. COVID-19 is becoming one of the most fatal pandemics in history and brings a huge challenge to the global healthcare system. Opportune detection, confinement, and early treatment of infected cases present the first step in combating COVID-19. Diagnosis via viral nucleic acid amplification tests (NAATs) is frequently employed and considered the standard procedure. However, with an increasing urge for point-of-care tests, rapid and cheaper immunoassays are widely utilized, such as lateral flow immunoassay (LFIA), which can be used for rapid, early, and large-scale detection of SARS-CoV-2 infection. In this narrative review, the principle and technique of LFIA applied in COVID-19 antigen and antibody detection are introduced. The diagnostic sensitivity and specificity of the commercial LFIA tests are outlined and compared. Generally, LFIA antigen tests for SARS-CoV-2 are less sensitive than viral NAATs, the “gold standard” for clinical COVID-19 diagnosis. However, antigen tests can be used for rapid and mass testing in high-risk congregate housing to quickly identify people with COVID-19, implementing infection prevention and control measures, thus preventing transmission. LFIA anti-SARS-CoV-2 antibody tests, IgM and/or IgG, known as serology tests, are used for identification if a person has previously been exposed to the virus or vaccine immunization. Notably, advanced techniques, such as LFT-based CRISPR-Cas9 and surface-enhanced Raman spectroscopy (SERS), have added new dimensions to the COVID-19 diagnosis and are also discussed in this review.

show abstract

“…Antibody testing for COVID-19 can serve as a complementary diagnostic tool to RT-PCR. As seroconversion is generally observed 3–14 days after symptom onset ( Jiang et al, 2022 ; Yamamoto et al, 2022 ) and antibody detection is simpler and faster than viral RNA load testing ( Kevadiya et al, 2021 ), it serves as a promising alternative tool for COVID-19 diagnosis ( Feng, 2020 ). Before vaccination, the detection of any of the nucleocapsid (N) protein, spike (S) protein, or receptor binding domain (RBD) antibodies during SARS-CoV-2 antibody testing indicated previous exposure to SARS-CoV-2.…”

Section: Introductionmentioning

confidence: 99%

Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment

Chen

Jian

Chang

et al. 2023

PeerJ

View full text Add to dashboard Cite

Purpose Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major healthcare threat worldwide. Since it was first identified in November 2021, the Omicron (B.1.1.529) variant of SARS-CoV-2 has evolved into several lineages, including BA.1, BA.2–BA.4, and BA.5. SARS-CoV-2 variants might increase transmissibility, pathogenicity, and resistance to vaccine-induced immunity. Thus, the epidemiological surveillance of circulating lineages using variant phenotyping is essential. The aim of the current study was to characterize the clinical outcome of Omicron BA.2 infections among hospitalized COVID-19 patients and to perform an immunological assessment of such cases against SARS-CoV-2. Patients and Methods We evaluated the analytical and clinical performance of the BioIC SARS-CoV-2 immunoglobulin (Ig)M/IgG detection kit, which was used for detecting antibodies against SARS-CoV-2 in 257 patients infected with the Omicron variant. Results Poor prognosis was noted in 38 patients, including eight deaths in patients characterized by comorbidities predisposing them to severe COVID-19. The variant-of-concern (VOC) typing and serological analysis identified time-dependent epidemic trends of BA.2 variants emerging in the outbreak of the fourth wave in Taiwan. Of the 257 specimens analyzed, 108 (42%) and 24 (9.3%) were positive for anti-N IgM and IgG respectively. Conclusion The VOC typing of these samples allowed for the identification of epidemic trends by time intervals, including the B.1.1.529 variant replacing the B.1.617.2 variant. Moreover, antibody testing might serve as a complementary method for COVID-19 diagnosis. The combination of serological testing results with the reverse transcription-polymerase chain reaction cycle threshold value has potential value in disease prognosis, thereby aiding in epidemic investigations conducted by clinicians or the healthcare department.

show abstract

<p>Clinical Value of SARS-CoV2 IgM and IgG Antibodies in Diagnosis of COVID-19 in Suspected Cases</p>

Cited by 5 publications

References 17 publications

Detection of IgG and IgM Levels in Patients with COVID-19 in Mosul Province, Iraq

Detection of IgG and IgM Levels in Patients with COVID-19 in Mosul Province, Iraq

Development and Efficacy of Lateral Flow Point-of-Care Testing Devices for Rapid and Mass COVID-19 Diagnosis by the Detections of SARS-CoV-2 Antigen and Anti-SARS-CoV-2 Antibodies

Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment

Contact Info

Product

Resources

About